OC
OC9.F Omnicell Inc
- Market cap
- EUR 1.43B
- P/E
- 37.8x
- P/B
- 1.24x
- ROE
- 4.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is OC9.F undervalued?
Graham numberOC9.F trades 44.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Omnicell Inc fundamental analysis
No fundamental analysis for Omnicell Inc yet.
Omnicell Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Omnicell Inc
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automatio…
Full company profileOmnicell Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Omnicell Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 693M | 716M | 787M | 897M | 892M | 1.13B | 1.30B | 1.15B | 1.11B | 1.18B | 1.24B |
| Gross Profit | 314M | 322M | 372M | 437M | 413M | 555M | 589M | 497M | 471M | 503M | 575M |
| Operating Income | 6.48M | 5.75M | 44.4M | 78.4M | 35.5M | 89.5M | -2.32M | -34.9M | 337K | 5.16M | 85.6M |
| EBITDA | - | 57.3M | 95.7M | 142M | 107M | 174M | 96.8M | 60.7M | 90.1M | 91.8M | 168M |
| Net Income | 603K | 20.6M | 37.7M | 61.3M | 32.2M | 77.8M | 5.65M | -20.4M | 12.5M | 2.05M | 62.3M |
| EPS | - | 0.54 | 0.94 | 1.46 | 0.75 | 1.77 | 0.13 | -0.45 | 0.27 | 0.05 | 1.35 |
| Balance Sheet | |||||||||||
| Total Assets | 935M | 980M | 1.08B | 1.24B | 1.82B | 2.14B | 2.21B | 2.23B | 2.12B | 1.97B | 2.06B |
| Total Liabilities | 503M | 463M | 402M | 396M | 857M | 996M | 1.08B | 1.04B | 878M | 743M | 740M |
| Shareholders' Equity | 432M | 517M | 680M | 845M | 968M | 1.15B | 1.13B | 1.19B | 1.24B | 1.23B | 1.32B |
| Cash & Short-term Investments | 54.5M | 32.4M | 67.2M | 127M | 486M | 349M | 330M | 468M | 369M | 197M | 315M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 49.9M | 24.8M | 104M | 145M | 186M | 232M | 77.8M | 225M | 188M | 127M | 208M |
| Capital Expenditure | 29.2M | 15.3M | 23.7M | 15.9M | 22.8M | 29.0M | 47.5M | 59.9M | 52.8M | 57.9M | 55.3M |
| Free Cash Flow | - | -5.71M | 49.6M | 83.3M | 131M | 173M | 17.0M | 165M | 135M | 69.4M | 152M |
| Ratios | |||||||||||
| ROE | 0.1% | 4.0% | 5.6% | 7.3% | 3.3% | 6.8% | 0.5% | -1.7% | 1.0% | 0.2% | 4.7% |
| ROA | 0.1% | 2.1% | 3.5% | 4.9% | 1.8% | 3.6% | 0.3% | -0.9% | 0.6% | 0.1% | 3.0% |
| Net Profit Margin | 0.1% | 2.9% | 4.8% | 6.8% | 3.6% | 6.9% | 0.4% | -1.8% | 1.1% | 0.2% | 5.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Omnicell Inc dividends
Omnicell Inc has not paid dividends in the last 9 fiscal years.
Who owns Omnicell Inc
- Insiders 2.13%
- Institutions 97.87%
- Public & others 0.00%
- Shares outstanding 46.0M
- Free float 44.8M
Omnicell Inc company profile
- Company name
- Omnicell Inc
- Ticker
- OC9.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Technology
- Employees
- 3,450
- Fiscal year end
- December
- Address
- 4220 North Freeway, Fort Worth, TX, United States, 76137
- Phone
- 877 415 9990
- Website
- omnicell.com
About Omnicell Inc
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
Omnicell Inc management
10- Mr. Randall A. LippsFounder, Executive Chairman & CEO · born 1957
- Mr. Nnamdi N. NjokuPresident & COO · born 1977
- Mr. H. Baird Radford IIIExecutive VP & CFO · born 1970
- Mr. Corey J. Manley J.D.Executive VP, Chief Legal & Administrative Officer and Corporate Secretary · born 1978
- Mr. Brian H. NuttVP, Chief Accounting Officer & Corporate Controller · born 1970
- Dr. Perry A. Genova Ph.D.Senior VP & CTO
- Mr. David UngerVice President of Investor Relations
- Mr. Tomer StavitskySenior VP & Chief Corporate Development Officer
- Ms. Stella PrefachSenior VP & Chief Marketing Officer
- Mr. Dave FordSVP & Chief People Officer